IIS launches IT Club for digital innovation

Ideal Indian School (IIS) recently inaugurated its IT Club, marking the beginning of a new era in technological innovation underscoring the school’s dedication to providing students with a state-of-

Website link :https://adquash.com/news_q.php?str=IIS-launches-IT-Club-for-digital-innovation

Ange Postecoglou says ‘we have to accept the referee’s decision’ after home loss

Tottenham manager Ange Postecoglou has called for an end to the questioning of officials’ decisions in order to prevent their authority being undermined. Spurs had two players sent off in the 4-1 de

Website link :https://adquash.com/news_q.php?str=Ange_Postecoglou_says_‘we_have_to_accept_the_referee’s_decision’_after_home_loss_941

This week in data: What the heck is data observability?

VentureBeat presents: AI Unleashed - An exclusive executive event for enterprise data leaders. Network and learn with industry peers . Learn More What is data observability (really)? And how are you s

Website link :https://adquash.com/news_q.php?str=This_week_in_data:_What_the_heck_is_data_observability_432

Tiragolumab by Genentech USA for Gastric Cancer: Likelihood of Approval

Tiragolumab is under clinical development by and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) in

Website link :https://adquash.com/news_q.php?str=Tiragolumab_by_Genentech_USA_for_Gastric_Cancer:_Likelihood_of_Approval_692

Bevacizumab biosimilar by Gedeon Richter for Metastatic Breast Cancer: Likelihood of Approval

Bevacizumab biosimilar is under clinical development by and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase tra

Website link :https://adquash.com/news_q.php?str=Bevacizumab_biosimilar_by_Gedeon_Richter_for_Metastatic_Breast_Cancer:_Likelihood_of_Approval_693

CBM-588 by Miyarisan Pharmaceutical for Hematopoietic Stem Cell Transplantation: Likelihood of Approval

CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Hematopoietic Stem Cell Transplantation. According to GlobalData, Phase I drugs for Hematopoietic Stem Ce

Website link :https://adquash.com/news_q.php?str=CBM-588_by_Miyarisan_Pharmaceutical_for_Hematopoietic_Stem_Cell_Transplantation:_Likelihood_of_Approval_695

Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplasti

Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Anaplastic_Large_Cell_Lymphoma_(ALCL):_Likelihood_of_Approval_698

IMM-65 by Portage Biotech for Solid Tumor: Likelihood of Approval

IMM-65 is under clinical development by Portage Biotech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTS

Website link :https://adquash.com/news_q.php?str=IMM-65_by_Portage_Biotech_for_Solid_Tumor:_Likelihood_of_Approval_699

Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval

Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Ce

Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Natural_Killer_Cell_Lymphomas:_Likelihood_of_Approval_700

The Path Forward for AI Must Be a Responsible One (Guest Column)

Throughout history, music has embraced constructive change and innovation. And we will do so again as we confront the opportunities and risks of artificial intelligence. Done right, AI should offer av

Website link :https://adquash.com/news_q.php?str=The-Path-Forward-for-AI-Must-Be-a-Responsible-One-Guest-Column

New Method Developed to Determine Exoplanet Habitability

New Method Developed to Determine Exoplanet Habitability A recent study conducted by an international team of researchers, including scientists from MIT and the University of Birmingham, has unveiled

Website link :https://adquash.com/news_q.php?str=New-Method-Developed-to-Determine-Exoplanet-Habitability

Groundbreaking Dual-Purpose Batteries Store Energy And Capture CO2

University of Surrey think efficient and cheap batteries that can also capture harmful CO 2 emissions could be right around the corner, thanks to a new system that speeds up the development of catalys

Website link :https://adquash.com/news_q.php?str=Groundbreaking_Dual-Purpose_Batteries_Store_Energy_And_Capture_CO2_483